SCHEMBL5715372

SCHEMBL5715372

Cc1ccc(CCc2ccc(OC(=O)N3CCN(c4ccc(C(F)(F)F)cn4)CC3)cc2)nc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.60
HPGD P15428 1/20 0.60
MEN1 O00255 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
KMT2A Q03164 1/20 0.54
KDM4E B2RXH2 7/20 0.51
LMNA P02545 6/20 0.51
HTT P42858 4/20 0.51
POLB P06746 2/20 0.47
LIPE Q05469 4/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 2/20 0.46
BCHE P06276 1/20 0.46
IDE P14735 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
ALDH1A1 P00352 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715132 0.92 SMN1; SMN2 (0.61) SMN1; SMN2HPGDMEN1CYP1A2CYP2C9
SCHEMBL5714131 0.92 SMN1; SMN2 (0.61) SMN1; SMN2HPGDMEN1CYP1A2CYP2C9
SCHEMBL5715223 0.92 AOC3 (0.52) SMN1; SMN2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL5715218 0.88 DRD2 (0.49) SMN1; SMN2HPGDHRH3AOC3PANK3
SCHEMBL5714351 0.88 SMN1; SMN2 (0.58) SMN1; SMN2HPGDMEN1CYP1A2CYP2C9
SCHEMBL5715468 0.87 SMN1; SMN2 (0.61) SMN1; SMN2HPGDMEN1CYP1A2CYP2C9
SCHEMBL5714809 0.86 PANK3 (0.47) SMN1; SMN2HPGDHRH3AOC3PANK3
SCHEMBL5714546 0.86 SMN1; SMN2 (0.58) SMN1; SMN2HPGDMEN1CYP1A2CYP2C9
SCHEMBL5714727 0.86 SMN1; SMN2 (0.62) SMN1; SMN2HPGDMEN1CYP1A2CYP2C9
SCHEMBL5714583 0.85 AOC3 (0.47) SMN1; SMN2HPGDKDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC SMN1; SMN2 2732/4885HPGD 793/4885MEN1 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.